Brokerages Expect Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Will Post Earnings of -$0.50 Per Share
Equities research analysts expect Rocket Pharmaceuticals Inc (NASDAQ:RCKT) to post ($0.50) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Rocket Pharmaceuticals’ earnings, with estimates ranging from ($0.75) to ($0.40). Rocket Pharmaceuticals reported earnings per share of ($0.40) in the same quarter last year, which would indicate a negative year-over-year growth rate of 25%. The firm is expected to report its next quarterly earnings results on Wednesday, November 6th.
On average, analysts expect that Rocket Pharmaceuticals will report full year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($2.43) to ($1.55). For the next financial year, analysts anticipate that the company will post earnings of ($2.44) per share, with EPS estimates ranging from ($3.55) to ($1.89). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Rocket Pharmaceuticals.
Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.10.
Rocket Pharmaceuticals stock traded up $0.52 during trading hours on Friday, reaching $14.09. 245,975 shares of the stock were exchanged, compared to its average volume of 302,368. The stock has a market cap of $679.70 million, a P/E ratio of -7.46 and a beta of 2.71. The company has a debt-to-equity ratio of 0.18, a quick ratio of 17.48 and a current ratio of 17.48. Rocket Pharmaceuticals has a 52-week low of $10.75 and a 52-week high of $25.96. The firm’s 50 day moving average is $11.68 and its 200 day moving average is $15.34.
Institutional investors and hedge funds have recently made changes to their positions in the company. Spark Investment Management LLC purchased a new position in shares of Rocket Pharmaceuticals in the 1st quarter valued at about $564,000. Zeke Capital Advisors LLC purchased a new position in shares of Rocket Pharmaceuticals in the 2nd quarter valued at about $153,000. Group One Trading L.P. increased its holdings in shares of Rocket Pharmaceuticals by 103.6% in the 1st quarter. Group One Trading L.P. now owns 1,999 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 1,017 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Rocket Pharmaceuticals in the 1st quarter valued at about $2,560,000. Finally, Marshall Wace North America L.P. purchased a new position in shares of Rocket Pharmaceuticals in the 1st quarter valued at about $3,073,000. Institutional investors and hedge funds own 97.15% of the company’s stock.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.
Further Reading: Are sell-side analysts objective?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.